Skip to main content
Premium Trial:

Request an Annual Quote

Aridhia, Glencoe Creating Software Tools for Personalized Medicine

NEW YORK (GenomeWeb News) – Aridhia Informatics and Glencoe Software today announced a partnership to develop products using real-world clinical, genetic, and research information in order to hasten the development of personalized therapies and improve patient outcomes.

The deal brings together Aridhia's capabilities in accessing, storing, and analyzing healthcare information and Glencoe's expertise in managing, sharing, and publishing large scientific datasets.

As part of the deal, Aridhia, based in Dundee, Scotland, will make a "major investment" in Seattle-based Glencoe. Financial details were not disclosed.

Both firms were founded based on technology developed at the University of Dundee. Formed in 2008, Aridhia is a health informatics joint venture between the university, NHS Tayside, and Sumerian and has received more than £6.5 million ($10.5 million) in investments in its history, it said.

Glencoe builds software tools for analyzing very large scientific image datasets.

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.